A Randomized, Controlled, Double-Blind Study Comparing the Survival Benefit of Four Different Reverse Transcriptase Inhibitor Therapies (Three-Drug, Two-Drug, and Alternating Drug) for the Treatment of Advanced AIDS
Keith Henry(Universität Hamburg), James O. Kahn(San Francisco General Hospital), John Phair(Icahn School of Medicine at Mount Sinai), Alejo Erice(Twin Cities Orthopedics), Antoinette Kenton(AIDS Clinical Trials Group), Margaret A. Fischl(University of Miami), Anne Kmack(Frontier Science & Technology Research Foundation, Inc.), Song-Heng Liou(Harvard University), Henry H. Balfour, Martin Hirsch(John Radcliffe Hospital), Camlin Tierney(Harvard University), Ana Martı́nez(Consejo Superior de Investigaciones Científicas)
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology
December 1, 1998
Cited by 86
Related Papers
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
|New England Journal of Medicine|1987|3k
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
|New England Journal of Medicine|1990|1.3k
The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
|New England Journal of Medicine|1987|1.2k
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
|The Lancet|2002|1.1k
Treatment for Adult HIV Infection
|JAMA|2006|1k